Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

JPMorgan Chase Lowers Expectations for BridgeBio Oncology Therapeutics Stock Price

Guavy AI Editorial Team
Instruments
JPM
Share

JPMorgan Chase & Co. has lowered its expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) stock price, reducing its target from $27.00 to $25.00 in a research note issued to investors on Friday.

The brokerage currently maintains an 'overweight' rating on the stock, indicating a potential upside of 172.12% from the company's current price.

This is not the first time analysts have weighed in on BridgeBio Oncology Therapeutics. Oppenheimer initiated coverage with an 'outperform' rating and a $22.00 price target, while UBS Group downgraded shares to an 'overweight' rating.

More on Stocks

Stocks just now

Birmingham Police Officer Fatally Shoots Man After Chase

Stocks 4m ago

Merck Executives Unload Millions in Company Stock

Stocks 4m ago

Merck Exec Exercises Options Worth $1.33M Amid Revenue Growth

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy